Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (5315)	1/3/2002 8:20:58 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 52153

Tough to say. From my perspective, I feel that it's a huge over reaction. If you go through the indications thread for autoimmunity/chronic infection, you'll see that I thought that the crappy psoriasis results were better than I expected. That is, I expected flat out failure. For RA, I could never understand why it was being tested at all. BUT!!....... for diseases where the neutrophil component is pronounced, I like the concept. I therefore consider COPD and some cancer indications to be of interest. Been looking at this for a long time as a lousy application of the "ICOS business plan"..... get a biological and test it against every indication known to man. I'm therefore surprised at the after hours damage, as I doubt that too many analysts had success in RA built into the potential revenue stream.